Prognostic And Predictive Role Of Circulating Angiopoietin-2 In Multiple Solid Tumors: An Analysis Of Approximately 500 Patients Treated With Lenvatinib Across Tumor Types.

11061 Background: Lenvatinib is an oral tyrosine kinase inhibitor targeting VEGFR1-3, FGFR1-4, RET, KIT, and PDGFRα. Two phase 3 trials in differentiated thyroid cancer [DTC] and hepatocellular cancer [HCC] are ongoing. Baseline levels (BL) of circulating cytokines and angiogenic factors (CAFs) were evaluated across multiple phase 2 trials in 6 different types of solid tumors. Methods: BL serum or plasma samples from a total of approximately 500 patients were analyzed for about 50 CAFs using ELISA and multiplex assay platforms* in 5 phase 2 trials of lenvatinib for thyroid cancer (DTC and medullary thyroid cancer [MTC]), HCC, glioblastoma, endometrial cancer (EC), and melanoma (with or without BRAF V600E). Correlation with clinical outcomes (objective response rate [ORR], overall survival [OS]) was performed using Wilcoxon signed-rank test and univariate Cox proportional hazard model, respectively, whereas correlation with tumor size prior to lenvatinib treatment was performed using the Spearmanu0027s rank co...